Skip to main content

Vasorin/SLIT-like 2 Antibody [FITC]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-18471F

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-18471F

Key Product Details

Species Reactivity

Human

Applications

Western Blot, Immunoprecipitation

Label

FITC (Excitation = 495 nm, Emission = 519 nm)

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Recognizes region between residues Between between 623 and 673..

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for Vasorin/SLIT-like 2 Antibody [FITC]

Application
Recommended Usage

Immunoprecipitation

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Affinity purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: Vasorin/SLIT-like 2

SLITL2 may act as an inhibitor of TGF-beta signaling

Alternate Names

Atia, SLIT like 2, Slitl2, VASN

Gene Symbol

VASN

Additional Vasorin/SLIT-like 2 Products

Product Documents for Vasorin/SLIT-like 2 Antibody [FITC]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Vasorin/SLIT-like 2 Antibody [FITC]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...